STOCK TITAN

Oncolytics Biotech (NASDAQ: ONCY) CBO receives 260,000 stock options at $1.06 exercise price

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

ONCOLYTICS BIOTECH INC Chief Business Officer Andrew Aromando received a grant of 260,000 stock options. These options have an exercise price of $1.06 per share, equal to the closing price of the company’s common stock on the Nasdaq Capital Market on June 1, 2026.

The options cover 260,000 underlying common shares and expire on June 1, 2036. They vest in three equal annual installments, with the first tranche vesting on June 1, 2027, subject to his continued service or employment on each vesting date.

Positive

  • None.

Negative

  • None.
Insider Aromando Andrew
Role Chief Business Officer
Type Security Shares Price Value
Grant/Award Stock Option 260,000 $0.00 --
Holdings After Transaction: Stock Option — 260,000 shares (Direct, null)
Footnotes (1)
  1. The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026. The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date.
Options granted 260,000 stock options Grant to Chief Business Officer on June 1, 2026
Exercise price $1.06 per share Equal to closing price on Nasdaq Capital Market on June 1, 2026
Underlying shares 260,000 common shares Shares issuable upon exercise of options
Expiration date June 1, 2036 Option term end date
Vesting start June 1, 2027 First of three equal annual vesting dates
Post-grant derivative holdings 260,000 options Total options held following this grant
Stock Option financial
"security_title: "Stock Option" and underlying_security_title: "Common Shares""
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise price financial
"The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Nasdaq Capital Market financial
"the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026"
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.
vests in three equal annual installments financial
"The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027"
expiration date financial
"expiration_date: "2036-06-01T00:00:00.000Z" for the stock option grant"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Aromando Andrew

(Last)(First)(Middle)
C/O ONCOLYTICS BIOTECH INC.
4350 EXECUTIVE DRIVE, SUITE 325

(Street)
SAN DIEGO CALIFORNIA 92121

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
ONCOLYTICS BIOTECH INC [ ONCY ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Business Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option$1.06(1)06/01/2026A260,000 (2)06/01/2036Common Shares260,000$0260,000D
Explanation of Responses:
1. The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026.
2. The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date.
/s/ Kirk Look, Attorney-in-Fact06/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did ONCY Chief Business Officer Andrew Aromando report on this Form 4?

Andrew Aromando reported receiving a grant of 260,000 stock options. These options give him the right to buy common shares at a fixed exercise price, as part of his compensation package, rather than reflecting any open-market stock purchase or sale.

What is the exercise price of Andrew Aromando’s ONCY stock options?

The stock options have an exercise price of $1.06 per share. This price equals the closing price of ONCOLYTICS BIOTECH INC common stock on the Nasdaq Capital Market on June 1, 2026, the date the options were granted.

How many ONCY shares are covered by Andrew Aromando’s new option grant?

The option grant covers 260,000 underlying common shares of ONCOLYTICS BIOTECH INC. If fully vested and exercised at the $1.06 exercise price, these options would convert into 260,000 common shares, subject to the stated vesting and expiration terms.

When do Andrew Aromando’s ONCY stock options vest?

The options vest in three equal annual installments, starting June 1, 2027. Each tranche requires Andrew Aromando’s continued service or employment with ONCOLYTICS BIOTECH INC on the applicable vesting date before those specific options become exercisable.

When do Andrew Aromando’s ONCY stock options expire?

The stock options expire on June 1, 2036. After that expiration date, any unexercised options will lapse and can no longer be used to purchase ONCOLYTICS BIOTECH INC common shares at the $1.06 exercise price.

Did Andrew Aromando buy or sell ONCY shares in the market?

The filing shows a grant of stock options coded as a grant or award, not an open-market trade. It reflects compensation-related acquisition of derivative securities, with no reported open-market buying or selling of ONCOLYTICS BIOTECH INC common shares.